Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Last trade$26.79
Day change-$1.22 (-4.36%)
Day range$26.74 – $28.49
Volume1,835,081
Market cap$4.66B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.66B
Price / earnings
—
Price / book
11.85×
Price / sales
4.86×
EV / sales
5.93×
EV / EBITDA
-10.33×
Profitability
Earnings per share
-$3.28
Return on assets
-18.76%
Return on equity
-138.84%
Dividend yield
0%
Liquidity and leverage
Debt / equity
3.36×
Current ratio
5.43×
Quick ratio
5.36×
Cash ratio
0.68×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$616.26M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IONS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$242.72M
$267.95M
$246.09M
$203.33M
$156.72M
$452.05M
$131.61M
$226.58M
Cost of revenue
$3.32M
$2.74M
$2.98M
$7.96M
$2.34M
$4.15M
$1.46M
$3.83M
Gross profit
$239.4M
$265.21M
$243.11M
$195.37M
$154.38M
$447.9M
$130.15M
$222.75M
Selling, general and administrative
$154.22M
$150.4M
$150.36M
$130.19M
$96.81M
$90.62M
$76.25M
$88.08M
Research and development
$215.88M
$217.11M
$210.17M
$279.65M
$217.75M
$217.46M
$200.76M
$245.49M
Total operating expenses
$370.1M
$367.5M
$360.53M
$409.83M
$314.56M
$308.08M
$277.01M
$333.57M
Operating income
-$130.7M
-$102.29M
-$117.42M
-$214.46M
-$160.18M
$139.82M
-$146.86M
-$110.82M
Interest expense
-$8.76M
-$22.12M
-$22.5M
-$22.69M
-$22.16M
-$22.76M
-$22.93M
-$22.86M
Income before taxes
-$110.11M
-$113.38M
-$92.31M
-$227.92M
-$128.39M
$123.53M
-$146.82M
-$107.04M
Income taxes
-$141K
$1.26M
$218K
$1.48M
$213K
-$20K
$116K
-$2.69M
Net income
-$109.97M
-$114.65M
-$92.53M
-$229.39M
-$128.61M
$123.55M
-$146.94M
-$104.35M
Net income attributable to common shareholders
-$109.97M
-$114.65M
-$92.53M
-$229.39M
-$128.61M
$123.55M
-$146.94M
-$104.35M
EBITDA
-$126.37M
-$98.16M
-$113.46M
-$213M
-$157.31M
$142.68M
-$144.05M
-$110.46M
Basic earnings per share
-$0.66
-$0.69
-$0.56
-$1.41
-$0.80
$0.78
-$0.93
-$0.66
Diluted earnings per share
-$0.66
-$0.69
-$0.56
-$1.65
-$0.80
$0.70
-$0.93
-$0.66
Recent news
Company coverage with links to the original publishers.
Ionis lowered its 2026 TRYNGOLZA revenue guidance to ~$50 million due to a slower-than-anticipated launch ramp, while DAWNZERA showed strong momentum with 40% quarterly sales growth to $37 million. However, Phase III clinical trial setbacks in partnered programs forced management to delay its positive cash flow target from 2028 to 2029, though the company maintains a $1.9 billion cash position.
ARS Pharmaceuticals (SPRY) is expected to report a quarterly loss of $0.34 per share with revenues of $42.69 million on November 5, 2026. The company has a negative Earnings ESP of -19.40% and Zacks Rank #4, making it unlikely to beat consensus estimates. SPRY has missed EPS estimates in all of the last four quarters.
Ionis Pharmaceuticals is expected to report Q3 2026 earnings with a year-over-year EPS decline of 63.9% to a loss of $1.00 per share, though revenues are projected to rise 14% to $178.93 million. With a negative Earnings ESP of -26.63% and Zacks Rank #3, the stock is not considered a compelling earnings-beat candidate. The company has a strong history of beating estimates in the last four quarters.
Novartis reported Q3 2026 core EPS of $2.46, beating estimates by 9.3%, with 9% year-over-year growth. However, revenues of $14.52 billion missed consensus by 0.2%. Strong sales from priority drugs like Kisqali, Kesimpta, and Scemblix offset generic competition. The company raised its core operating income guidance but faced pipeline setbacks with del-desiran and pelacarsen failing to meet primary endpoints.
Roche announced positive interim phase III data from the IMAgINATION study showing that investigational sefaxersen achieved a statistically significant 43.1% reduction in proteinuria relative to placebo at 37 weeks in adults with primary IgA nephropathy. The antisense oligonucleotide inhibitor of complement factor B was well tolerated with no new safety signals and is designed as a once-monthly subcutaneous injection for self-administration.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.